Andrew Dickinson Sells 2,500 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $125.23, for a total transaction of $313,075.00. Following the sale, the chief financial officer directly owned 154,555 shares in the company, valued at approximately $19,354,922.65. The trade was a 1.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Gilead Sciences Trading Up 2.5%

Shares of NASDAQ GILD traded up $3.09 during mid-day trading on Tuesday, reaching $127.18. 8,175,751 shares of the company’s stock were exchanged, compared to its average volume of 7,956,847. The company’s 50-day moving average is $117.61 and its 200-day moving average is $113.02. The firm has a market capitalization of $157.79 billion, a price-to-earnings ratio of 25.33, a PEG ratio of 0.81 and a beta of 0.32. Gilead Sciences, Inc. has a 52-week low of $86.08 and a 52-week high of $127.68. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be issued a $0.79 dividend. The ex-dividend date is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on GILD. JPMorgan Chase & Co. upped their price target on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. Dbs Bank upgraded shares of Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Needham & Company LLC increased their target price on shares of Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Finally, Wolfe Research increased their price objective on Gilead Sciences from $135.00 to $140.00 and gave the stock an “outperform” rating in a research report on Thursday, October 23rd. Two analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $129.13.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. One Wealth Advisors LLC grew its holdings in Gilead Sciences by 34.8% in the second quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock valued at $1,016,000 after purchasing an additional 2,364 shares during the last quarter. Ariel Investments LLC increased its stake in shares of Gilead Sciences by 7.7% during the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock worth $48,229,000 after purchasing an additional 30,630 shares in the last quarter. Simplify Asset Management Inc. lifted its stake in Gilead Sciences by 148.6% in the 2nd quarter. Simplify Asset Management Inc. now owns 52,890 shares of the biopharmaceutical company’s stock valued at $5,864,000 after buying an additional 31,618 shares in the last quarter. Sivik Global Healthcare LLC raised its holdings in shares of Gilead Sciences by 25.0% in the second quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $5,544,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Wealth Management Associates Inc. acquired a new stake in shares of Gilead Sciences during the second quarter valued at $255,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.